Since its inception in the summer of 2012, the Breakthrough Therapy designation has been the most coveted pathway for biopharmaceutical companies and for patients with serious or life threatening diseases or conditions seeking substantial improvement over existing therapies. "Preliminary clinical evidence" is the gateway to this pathway.

This webcast will include:

• Understand the difference and overlap of the multiple expedited pathways and why the breakthrough designation is so coveted
• Recognize the vital role that imaging has played in the Breakthrough Therapy approvals to date and highlight lessons learned
• Understand real-world operational challenges along the path to Breakthrough Therapy approval

Who Should Attend:

This webinar is designed for both medical and non-medical staff within the biopharmaceutical industry with roles in clinical research, clinical operations, project management, regulatory development, regulatory affairs, and medical affairs.

Registration
A valid business Email address is required to attend.